Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

DARMSTADT, Germany and NEW YORK, November 19, 2018 -- (Healthcare Sales & Marketing Network) -- Merck KGaA, Darmstadt, Germany, and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combi... Biopharmaceuticals, Oncology Merck KGaA, Pfizer, avelumab, ovarian cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news